Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Mortality 80% Improvement Relative Risk Hospitalization -5% Recovery -5% Viral load, day 28 -4% Viral load, day 7 4% c19early.com/cp Alemany et al. NCT04621123 Conv. Plasma RCT EARLY Favors conv. plasma Favors control
Alemany, 376 patient convalescent plasma early treatment RCT: 80% lower mortality [p=0.5], 5% higher hospitalization [p=1], 5% worse recovery [p=0.67], and 4% worse viral clearance [p=0.33] https://c19p.org/alemany
copied to clipboard
High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial
Alemany et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00545-2, NCT04621123 (history)
9 Feb 2022    Source   PDF   Share   Tweet
RCT 188 convalescent plasma and 188 control patients, showing no significant difference in outcomes.
risk of death, 80.0% lower, RR 0.20, p = 0.50, treatment 0 of 188 (0.0%), control 2 of 188 (1.1%), NNT 94, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of hospitalization, 4.8% higher, RR 1.05, p = 1.00, treatment 22 of 188 (11.7%), control 21 of 188 (11.2%).
risk of no recovery, 5.0% higher, HR 1.05, p = 0.67, treatment 188, control 188, time to symptom resolution.
viral load, 3.6% higher, relative load 1.04, p = 0.33, treatment 188, control 188, relative change in viral load, day 28.
viral load, 3.7% lower, relative load 0.96, p = 0.42, treatment 188, control 188, relative change in viral load, day 7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Alemany et al., 9 Feb 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Spain, peer-reviewed, median age 56.0, 108 authors, study period 10 November, 2020 - 28 July, 2021, trial NCT04621123 (history).
Contact: aalemany@flsida.org.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit